Effects of the novel acetylcholinesterase inhibitor N-octyl-1,2,3,4- tetrahydro-9-aminoacridine on locomotor activity and avoidance learning in mice

Neurobiology of Learning and Memory

Volumn 71, Issue 3, 1999, Pages 301-307

  Capone, Francesca ^a   Oliverio, Alberto ^a,b   Pomponi, Massimo ^c   Marta, Maurizio ^c   Gatta, Franco ^d   Pavone, Flaminia ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d CNR   (Italy)

Author keywords

Acetylcholinesterase inhibitor; Active avoidance; Locomotor activity; Mice; Tacrine; THA C8

Indexed keywords

CHOLINESTERASE INHIBITOR; TACRINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG PENETRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN;

EID: 0032839058     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1006/nlme.1998.3883     Document Type: Article

References (30)

1. Adem A. The next generation of cholinesterase inhibitors. Acta Neurologica Scandinavica Supplement. 149:1993;10-12.
2. Bartus R. T., Dean R. L. III, Beer B., Lippa A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
3. Brufani M., Castellano C., Marta M., Oliverio A., Pagella P. G., Pavone F., Pomponi M., Rugarli P. L. A long lasting cholinesterase inhibitor affecting neuronal and behavioral processes. Pharmacology, Biochemistry, and Behavior. 26:1987;625-629.
4. Camacho F., Smith C. P., Vergas H. M., Winslow J. T. Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology. 124:1996;347-354.
5. Chatelier G., Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial. British Medical Journal. 300:1990;495-499.
6. Davis K. L., Thal L. J., Gamzu E. A double-blind, placebo controlled multicenter study of tacrine for Alzheimer disease. New England Journal of Medicine. 327:1992;1253-1259.
7. Davis K. L., Powchik P. Tacrine. The Lancet. 345:1995;625-630.
8. Dawson G. R., Bentley G., Draper F., Rycroft W., Iversen S. D., Pagella P. G. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents. Pharmacology, Biochemistry, and Behavior. 39:1991;865-871.
9. De Sarno P., Pomponi M., Giacobini E., Tang X. C., Williams E. The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochemical Research. 14:1989;971-977.
10. Farlow M., Gracon S. I., Hershey L. A., Lewis K. W., Sadowsky C. H., Dolan-Reno J. A controlled trial of tacrine in Alzheimer's disease. Journal of the American Medical Association. 268:1992;2523-2529.
11. FDC Report, 1993, 6, 8.
12. Flood J. F., Cherkin A. Effect of acute arecoline, tacrine, and arecoline+tacrine post-training administration on retention in old mice. Neurobiology of Aging. 9:1988;5-8.
13. Freeman S. E., Dawson R. M. Tacrine: A pharmacological review. Progress in Neurobiology. 36:1991;257-277.
14. Hagan J. J., Jansen J. H. M., Broekkamp C. L. E. Hemicolinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Psychopharmacology. 98:1989;347-356.
15. Hunter A. J., Murray T. K., Jones J. A., Cross A. J., Green A. R. The cholinergic pharmacology of tetrahydroaminoacridinein vivoin vitro. British Journal of Pharmacology. 98:1989;79-86.
16. Iijima S., Greig N. H., Garofalo P., Spangler E. L., Heller B., Brossi A., Ingram D. K. Phenserine: A physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology. 112:1993;415-420.
17. Knapp M. J., Knopman D. S., Salomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association. 271:1994;985-991.
18. Levy R. Tetrahydroaminoacridine and Alzheimer's disease. The Lancet. i:1987;139-141.
19. Maltby N., Broe G. A., Creasey H., Jorm A. F., Christensen H., Brooks W. S. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial. British Medical Journal. 308:1994;879-883.
20. Marta M., Castellano C., Oliverio A., Pavone F., Pagella P. G., Brufani M., Pomponi M. New analogs of physostigmine: Alternative drugs for Alzheimer's disease. Life Sciences. 43:1988;1921-1928.
21. Murray T. K., Cross A. J., Green A. R. Reversal by tetrahydroaminoacridine of scopolamine-induced memory and performance deficits in rats. Psychopharmacology. 105:1991;134-136.
22. Pavone F., Capone F., Battaglia M., Sansone M. Shuttle-box avoidance learning in mice: Improvement by combined glucose and tacrine. Neurobiology of Learning and Memory. 69:1998;204-210.
23. Pomponi M., Giardina B., Gatta F., Marta M. Physostigmine and tetrahydroaminoacridine analogs as alternative drugs for the treatment of Alzheimer's disease. Medicinal Chemistry Research. 2:1992;306-327.
24. Pomponi M., Marta M., Colella A., Sacchi S., Patamia, Gatta F., Capone F., Oliverio A., Pavone F. Studies on a new series of THA analogues: Effects of the aromatic residues that line the Gorge of AChE. FEBS Letters. 409:1997;155-160.
25. Riekkinen P. Jr., Aaltonen M., Sirvio J., Riekkinen P. Tetrahydroaminoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits. Physiology and Behavior. 49:1991a;1142-1152.
26. Riekkinen P. Jr., Sirvio J., Aaltonen M., Riekkinen P. Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats. Pharmacology, Biochemistry, and Behavior. 39:1991b;841-846.
27. Rupniak N. M. J., Field M. J., Samson N. A., Steventon M. J., Iversen S. D. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiology of Aging. 11:1990;609-613.
28. Sansone M., Libri V., Pavone F., Ammassari-Teule M. Effects of oxiracetam-scopolamine combinations on shuttle-box avoidance acquisition in mice. Archives Internationales de Pharmacodynamie et de Thérapie. 291:1988;208-216.
29. Shibanoki S., Ishii Y., Kubo T., Kogure M., Asai S., Ishikawa K. Effect of 9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta-(b)-quinoline monohydrate hydrochloride (NIC-247) on cholinergic enzyme activity in rats. Pharmacology, Biochemistry, and Behavior. 39:1991;499-502.
30. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New England Journal of Medicine. 315:1986;1241-1245.